Keith A. Goldan's departure as Chief Financial Officer of Syndax Pharmaceuticals Inc was reported, effective November 9, 2026; the filing names no successor. As of November 6, 2026, Syndax Pharmaceuticals Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 10, 2026 to November 2, 2026, naming 1 departure (Form 8-K, November 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Syndax Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Syndax Pharmaceuticals Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-10 to 2026-11-02. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Syndax Pharmaceuticals Inc files it.
Also on the record for Syndax Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 6.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 2.3% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.05% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.3% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 7.16% of the class | 5%+ stakes | Source |
| August 18, 2025 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 2.7% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by THE GOLDMAN SACHS GROUP, INC. | 6.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Syndax Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Syndax Pharmaceuticals Inc and the records around it.
Syndax Pharmaceuticals Inc elsewhere on the record
Companies that share a holder
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
- THE GOLDMAN SACHS GROUP, INC. also filed stake reports on 173 other companies: AEON ACQUISITION I CORP. (Nov 2026), ALPEX ACQUISITION CORPORATION (Nov 2026), ARCHIMEDES TECH SPAC PARTNERS II CO. (Nov 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Watch Syndax Pharmaceuticals Inc
Get an email when Syndax Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Syndax Pharmaceuticals Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Syndax Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Syndax Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-02 | Out | Chief Financial Officer | 2026-11-09 | 8-K, 2026-11-02 | |
| 2026-06-10 | Reported | not named in the filing | 8-K, 2026-06-10 |
Who leads Syndax Pharmaceuticals Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Keith A. Goldan, departure reported, effective 2026-11-09 (filed 2026-11-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Syndax Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Syndax Pharmaceuticals Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Syndax Pharmaceuticals IncEvery change, in the filing's words
Departing: Keith A. Goldan, Chief Financial Officer, effective 2026-11-09
On November 2, 2026, the Company issued a press release announcing that Keith A. Goldan will retire as the Company's Chief Financial Officer, principal accounting and financial officer and treasurer effective November 9, 2026, after which he will continue as an advisor for an interim period until his retirement.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
- Prior to his retirement date, Mr. Goldan will assist with the transition of his responsibilities.
- Mr. Goldan's compensation as an advisor will be materially consistent with his current compensation.
- The Company thanks Mr. Goldan for his dedicated service to the Company as its Chief Financial Officer.
- The Company also announced that Aaron A. Ondrey will join the Company as Chief Financial Officer, effective November 9, 2026.
- In connection with Mr. Ondrey's appointment as Chief Financial Officer, the Company's board of directors also appointed him principal accounting and financial officer and treasurer of the Company.
- Prior to joining the Company, Mr. Ondrey served as Chief Financial Officer of Beren Therapeutics, a private company, since September 2025.
- Before joining Beren, Mr. Ondrey was Chief Financial Officer of Rocket Pharmaceuticals, a publicly traded company, from March 2024 until September 2025, and Chief Financial Officer of Mirati Therapeutics, a publicly traded company from September 2023 until January 2024, and Senior Vice President, FP&A, from July 2022 through August 2023.
- From January 2020 until July 2022, Mr. Ondrey served as Vice President, Finance, at Arena Pharmaceuticals, a publicly traded company.
Reported
If all or any portion of an award granted under the 2015 Plan that is outstanding as of June 10, 2026 (an " Existing Award "), expires or is cancelled, forfeited, exchanged, settled for cash or otherwise terminated without the actual delivery of shares, any shares subject to such Existing Award will again be available for new awards under the 2026 Plan.
- At the Syndax Pharmaceuticals, Inc. (the "Company") 2026 Annual Meeting of Stockholders (the "Annual Meeting"), the Company's stockholders approved the Company's 2026 Equity Incentive Plan (the "2026 Plan"), which the Board of Directors of the Company (the "Board") previously approved, subject to stockholder approval at the Annual Meeting.
- As a result, the 2026 Plan became effective on June 10, 2026.
- No further awards will be granted under the Company's 2015 Omnibus Incentive Plan (the "2015 Plan") following its expiration on March 6, 2026.
- The 2026 Plan provides for the grant of incentive stock options to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors, and consultants, including employees and consultants of the Company's affiliates.
- The 2026 Plan provides for the reservation of 7,200,000 shares of the Company's common stock, plus the number of shares that become available for delivery under the 2015 Plan with respect to Existing Awards (as defined below) in accordance with the share recycling provisions described below.
Tools for this story
Each opens in a new tab, filled in for Syndax Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.